Expanded statistical analysis plan for legacy and long-term effects of aspirin in the ASPREE-XT observational follow-up study of participants in the ASPREE randomized trial
Preprint
Abstract
The ASPREE randomized controlled trial (2010-2017) of 19,114 community-dwelling older adults without cardiovascular disease and significant disability compared daily 100mg aspirin to placebo. A total of 16,317 (93%) of 17,546 surviving and non-withdrawn participants agreed to continue regular study follow-up visits in the post-trial phase, named ASPREE-XT (2017-2024). We present a statistical analysis plan to underpin three main papers to report aspirin effects through to the fourth post-trial ASPREE-XT study visit with focus areas of: (1) death, dementia, and disability, (2) CVD events and bleeding, and (3) cancer. The focus of the plan is to estimate long-term (entire timespan of RCT plus post-trial) and legacy (post-trial period only) effects of aspirin in the setting of primary prevention for older individuals. Preliminary insights to these effects are presented that are based on data that has been reported to the study’s observational study monitoring board however formal data lock is not expected until October 2023.Keywords
This publication has 19 references indexed in Scilit:
- Health Characteristics and Aspirin Use in Participants at the Baseline of the ASPirin in Reducing Events in the Elderly – eXTension (ASPREE-XT) Observational StudyContemporary Clinical Trials, 2023
- Aspirin Use to Prevent Cardiovascular Disease and Colorectal CancerJAMA, 2022
- Prediction of disability-free survival in healthy older peopleGeroScience, 2022
- A methods review of posttrial follow-up studies of cardiovascular prevention finds potential biases in estimating legacy effectsJournal of Clinical Epidemiology, 2021
- Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding EventsJAMA, 2019
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trialThe Lancet, 2018
- TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHESInternational Journal of Technology Assessment in Health Care, 2016
- Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trialsThe Lancet, 2012
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStatistics in Medicine, 2011
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009